Flamingo Therapeutics (“Flamingo”) today announced that an abstract has been accepted for presentation at the American Association for Cancer Research (AACR) annual meeting being held in Chicago, IL from April 25-30, 2025.
Flamingo Therapeutics (“Flamingo”) announced today its participation in the following upcoming investor conferences:
Flamingo Therapeutics ("Flamingo") today announced that an abstract has been selected for presentation at the 66th Annual ASH Annual Meeting and Exposition, being held in San Diego, CA from December 7-9, 2024.
Flamingo Therapeutics (“Flamingo”) today announced an oral presentation at the AACR Special Conference in Cancer Research, RNAs as Drivers, Targets, and Therapeutics in Cancer, being held in Seattle, Washington from November 14-17, 2024.
Flamingo Therapeutics (“Flamingo”) announced today its participation in the following upcoming investor conferences:
Flamingo Therapeutics (“Flamingo”) today announced that the PEMDA-HN trial has expanded beyond the United States into the UK and Korea.
Flamingo Therapeutics (“Flamingo”) today announced a poster presentation on FLM-7523 (also referred to as FTX-001) at the Annual Congress of the European Association for Cancer Research (EACR) 2024 Congress, being held in Rotterdam, Netherlands from June 10-13, 2024.
Flamingo Therapeutics (“Flamingo”) today announced the presentation of a Trial-in-Progress poster at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO 2024) taking place in Chicago, Illinois.
Flamingo Therapeutics (“Flamingo”) today announced that the first patient has been dosed in an Investigator-initiated Trial (IIT) evaluating the safety and efficacy of danvatirsen in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who have relapsed or are refractory to frontline therapy.
Flamingo Therapeutics (“Flamingo”) today announced its participation in the following upcoming investor and industry conferences: